| Typicality: | 0.369 |
| Saliency: | 0.278 |
| as an investigator-initiated trial | 2 | manner |
| trial → be funded by → astrazeneca | 12 |
| trial → be sponsored by → astrazeneca | 5 |
| negative | neutral | positive |
| 0.030 | 0.889 | 0.081 |
| Raw frequency | 17 |
| Normalized frequency | 0.278 |
| Modifier score | 0.500 |
| Perplexity | 28.984 |